DexCom, Inc.
NASDAQ:DXCMMedical - Devices
+$0.90 today
- Market cap
- $30.78B
- Beta
- 1.44
- P/E (TTM)
- 29.9
- EPS (TTM)
- $2.42
Volume 4.25M
Average 5.43M
DXCM EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
DexCom, Inc.NASDAQ: DXCM
EPS (Diluted) · Q2 FY2026 · quarter ended Jun 2026
EPS (Diluted) grows, but more slowly than its trailing trend
Q2 FY2026 EPS (Diluted) of $0.64 rose 42.2% year over year, behind the +75.7% change in trailing-twelve-month EPS (Diluted). Sequentially, it rose 25.5% from the prior quarter. Over 3 fiscal years it compounded at +37.7% a year.
Context
- EPS (Diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 15 analysts of $2.7 (+29.3%) for the fiscal year ending Dec 2026, a slowdown from the +47.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $0.64+25.5% QoQ
- Last fiscal yearDec 2025
- $2.09+47.2% YoY
- LTMJun 2026
- $2.53+75.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +42.2% | -3.6% | -45.8 pp |
| 1 year | +47.2% | +29.3% | -17.9 pp |
| 3-year CAGR | +37.7% | +21.1% | -16.6 pp |
| 5-year CAGR | +18.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- 2.09 USD
- Year-over-year change
- +47.2%
- 4-year CAGR
- +42.3%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.09 | +47.2% |
| FY2024 | 2024-12-31 | 1.42 | +9.2% |
| FY2023 | 2023-12-31 | 1.30 | +62.5% |
| FY2022 | 2022-12-31 | 0.80 | +56.9% |
| FY2021 | 2021-12-31 | 0.51 | — |
EPS (Diluted) vs competitors
How DXCM compares with its peers on the latest reported figures
- DXCM's LTM Jun 2026 EPS (Diluted) of $2.53 is the 2nd highest of the 7 companies compared; the peer median is -$1.25.
- Its year-over-year change of +75.7% is the 2nd highest of 6, against a peer median of +53.3%.
- Over three fiscal years its annual growth of +37.7% compares with a peer median of +275.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $5.35 | +62.6% | +275.4% | |
| LTM Jun 2026 | $2.53 | +75.7% | +37.7% | |
| LTM Mar 2026 | $2.25 | +1347.9% | — | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | -$1.1 | — | — |
| LTM Mar 2026 | -$1.4 | +49.7% | — | |
| LTM Mar 2026 | -$1.51 | +53.3% | — | |
| LTM Mar 2026 | -$2.16 | +5.7% | — | |
MMEDVMiniMed Group, Inc. | — | — | — | — |
| Peer median (excluding DXCM) | -$1.25 | +53.3% | +275.4% | |
Competitors are the stored peer set for DXCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.45B | 2.91B | 3.62B | 4.03B | 4.66B |
| Cost of Revenue | 768M | 1.03B | 1.33B | 1.59B | 1.86B |
| Gross Profit | 1.68B | 1.88B | 2.29B | 2.44B | 2.8B |
| Gross Margin | 68.6% | 64.7% | 63.2% | 60.5% | 60.1% |
| Research & Development | 604.2M | 484.2M | 505.8M | 552.4M | 599.1M |
| Selling, General & Admin | 810.5M | 1.01B | 1.19B | 1.29B | 1.29B |
| Operating Expenses | 1.41B | 1.49B | 1.69B | 1.84B | 1.89B |
| Depreciation & Amortization | 102M | 155.9M | 186M | 217.7M | 251.8M |
| EBITDA | 377.6M | 565.3M | 916.7M | 945.7M | 1.36B |
| EBITDA Margin | 15.4% | 19.4% | 25.3% | 23.4% | 29.1% |
| Operating Income | 265.8M | 391.2M | 597.7M | 600M | 911.8M |
| Operating Margin | 10.9% | 13.4% | 16.5% | 14.9% | 19.6% |
| Interest Income | 1.7M | 23.8M | 135M | 134.2M | 112.7M |
| Interest Expense | 18.8M | 18.6M | 20.3M | 19M | 18.3M |
| Other Income / Expenses | (9M) | (400K) | 112.7M | 109M | 176.6M |
| Income Before Tax | 256.8M | 390.8M | 710.4M | 709M | 1.09B |
| Pre-Tax Margin | 10.5% | 13.4% | 19.6% | 17.6% | 23.3% |
| Income Tax Expense | 39.9M | 49.6M | 168.9M | 132.8M | 252.1M |
| Net Income | 216.9M | 341.2M | 541.5M | 576.2M | 836.3M |
| Net Margin | 8.9% | 11.7% | 14.9% | 14.3% | 17.9% |
| EPS (Basic) | 0.56 | 0.88 | 1.44 | 1.46 | 2.14 |
| EPS (Diluted) | 0.51 | 0.80 | 1.30 | 1.42 | 2.09 |
| Weighted Avg Shares | 386.9M | 389.4M | 386M | 404.63M | 390.2M |
| Weighted Avg Shares (Diluted) | 428.8M | 427.5M | 425.5M | 412.7M | 405.5M |
DexCom, Inc.
NASDAQ:DXCM
Intrinsic Alpha fair value
Locked
Current Price
$82.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.